OBJECTIVE: To characterize the etiology of upper respiratory symptoms in elite athletes presenting to a sports physician for treatment. DESIGN: Prospective clinical and laboratory investigations. SETTING: Sports medicine clinic. PARTICIPANTS: Seventy elite-level athletes. MAIN OUTCOME MEASUREMENTS: Physician-recorded symptoms and diagnosis; health/training questionnaires; laboratory investigations of respiratory pathogens, white blood cell differential counts, and immune parameters. RESULTS: Physicians characterized 89% of presentations as viral or bacterial upper respiratory tract infection. Only 57% of presentations were associated with an identified pathogen or other laboratory parameters indicative of infection. Demographic information, previous illness, and training history did not distinguish between presentations with or without objective measures of infection. Elevated white blood cell and neutrophil counts and lower vitamin D concentrations partially distinguished infectious episodes. The number of systemic symptoms/behaviors at presentation (cough, headache, earache, fatigue, fever/rigors, myalgia/arthralgia, or cessation of training before clinic attendance) had some predictive value for infection: odds ratio per symptom, 1.23 (90% confidence interval: 0.91 to 1.66); probability of infection, 48% with no symptoms to 77% with 6 symptoms. Laboratory investigation identified allergy in a considerable proportion of the cohort (39%). CONCLUSIONS: The discrepancy between physician and laboratory diagnosed infection in elite athletes highlights the need for consideration of alternate diagnostic options when evaluating upper respiratory symptoms in athletes. A considerable proportion of episodes of respiratory symptoms in athletes were not associated with identification of a respiratory pathogen; other potentially treatable causes of upper respiratory symptoms should be considered, particularly in athletes with recurrent symptoms.
OBJECTIVE: To characterize the etiology of upper respiratory symptoms in elite athletes presenting to a sports physician for treatment. DESIGN: Prospective clinical and laboratory investigations. SETTING: Sports medicine clinic. PARTICIPANTS: Seventy elite-level athletes. MAIN OUTCOME MEASUREMENTS: Physician-recorded symptoms and diagnosis; health/training questionnaires; laboratory investigations of respiratory pathogens, white blood cell differential counts, and immune parameters. RESULTS: Physicians characterized 89% of presentations as viral or bacterial upper respiratory tract infection. Only 57% of presentations were associated with an identified pathogen or other laboratory parameters indicative of infection. Demographic information, previous illness, and training history did not distinguish between presentations with or without objective measures of infection. Elevated white blood cell and neutrophil counts and lower vitamin D concentrations partially distinguished infectious episodes. The number of systemic symptoms/behaviors at presentation (cough, headache, earache, fatigue, fever/rigors, myalgia/arthralgia, or cessation of training before clinic attendance) had some predictive value for infection: odds ratio per symptom, 1.23 (90% confidence interval: 0.91 to 1.66); probability of infection, 48% with no symptoms to 77% with 6 symptoms. Laboratory investigation identified allergy in a considerable proportion of the cohort (39%). CONCLUSIONS: The discrepancy between physician and laboratory diagnosed infection in elite athletes highlights the need for consideration of alternate diagnostic options when evaluating upper respiratory symptoms in athletes. A considerable proportion of episodes of respiratory symptoms in athletes were not associated with identification of a respiratory pathogen; other potentially treatable causes of upper respiratory symptoms should be considered, particularly in athletes with recurrent symptoms.
Authors: José Mário Morgado; Luís Rama; Isabel Silva; Maria de Jesus Inácio; Ana Henriques; Paula Laranjeira; Susana Pedreiro; Fátima Rosado; Francisco Alves; Michael Gleeson; Maria Luísa Pais; Artur Paiva; Ana Maria Teixeira Journal: Eur J Appl Physiol Date: 2011-05-17 Impact factor: 3.078
Authors: Luís Rama; Ana Maria Teixeira; Alice Matos; Grasiely Borges; Ana Henriques; Michael Gleeson; Susana Pedreiro; Edith Filaire; Francisco Alves; Artur Paiva Journal: Eur J Appl Physiol Date: 2012-09-19 Impact factor: 3.078
Authors: José P Morgado; Cristina P Monteiro; Catarina N Matias; Joana F Reis; Júlia Teles; Maria José Laires; Francisco Alves Journal: Eur J Appl Physiol Date: 2018-01-08 Impact factor: 3.078
Authors: Bethany C Diment; Matthew B Fortes; Julie P Greeves; Anna Casey; Ricardo J S Costa; Robert Walters; Neil P Walsh Journal: Eur J Appl Physiol Date: 2011-08-06 Impact factor: 3.078
Authors: Lari Pyöriä; Maarit Valtonen; Raakel Luoto; Wilma Grönroos; Matti Waris; Olli J Heinonen; Olli Ruuskanen; Maria F Perdomo Journal: Pathogens Date: 2021-05-28